scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1093/HUMREP/DEW149 |
P698 | PubMed publication ID | 27343272 |
P50 | author | Paul Devroey | Q7150251 |
Peter Humaidan | Q54217726 | ||
P2093 | author name string | L B Schwartz | |
K Gordon | |||
B C Tarlatzis | |||
J L Frattarelli | |||
B J Stegmann | |||
C C Coddington | |||
H M Fatemi | |||
P Lutjen | |||
S M Nelson | |||
P2860 | cites work | Distinction between early and late ovarian hyperstimulation syndrome | Q48891954 |
Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization | Q48919257 | ||
Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome | Q58377209 | ||
Hydroxyethyl Starches | Q29011237 | ||
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review | Q30877789 | ||
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club | Q33966809 | ||
Role of vascular endothelial growth factor in ovarian physiology and pathology | Q34023513 | ||
Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). | Q34183801 | ||
Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review | Q35011448 | ||
New concepts in the understanding of the ovarian hyperstimulation syndrome | Q35176568 | ||
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy | Q36060453 | ||
Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. | Q37539018 | ||
Preventing ovarian hyperstimulation syndrome: guidance for the clinician. | Q37736733 | ||
An OHSS-Free Clinic by segmentation of IVF treatment | Q37914493 | ||
Safety of modern starches used during surgery | Q38056899 | ||
Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement | Q38250026 | ||
Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases | Q38253309 | ||
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles | Q42166546 | ||
The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor | Q42468683 | ||
Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome | Q43408204 | ||
Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study | Q43625247 | ||
Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH. | Q43917543 | ||
Elective frozen replacement cycles for all: ready for prime time? | Q44478394 | ||
Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme | Q44659290 | ||
Maternal death related to IVF in the Netherlands 1984-2008. | Q44915965 | ||
Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization | Q45773434 | ||
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. | Q45927696 | ||
Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniques | Q46802412 | ||
GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'. | Q48597751 | ||
International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. | Q48667199 | ||
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction | Q48794435 | ||
Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study | Q48819444 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | ovarian hyperstimulation syndrome | Q1760461 |
P304 | page(s) | 1997-2004 | |
P577 | publication date | 2016-06-23 | |
P1433 | published in | Human Reproduction | Q5937357 |
P1476 | title | Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials | |
P478 | volume | 31 |
Q38371465 | A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial |
Q36375024 | Analysis of Chromosome Segregation, Histone Acetylation, and Spindle Morphology in Horse Oocytes |
Q49988311 | Clinical parameters of ovarian hyperstimulation syndrome (OHSS) following different hormonal triggers of oocyte maturation in IVF treatment. |
Q60907354 | Effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilisation in women with high antral follicle count: study protocol for a randomised controlled trial |
Q51739856 | Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention. |
Q88991253 | Genome-wide screening differential long non-coding RNAs expression profiles discloses its roles involved in OHSS development |
Q33770533 | GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis |
Q94335455 | Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF/ICSI |
Q47848951 | Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder |
Q33883193 | Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys |
Q48510887 | Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update |
Q51110367 | Prevention and management of ovarian hyperstimulation syndrome. |
Q41148132 | Quadrupling efficiency in production of genetically modified pigs through improved oocyte maturation |
Q60922316 | Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients |
Q90171167 | TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome |
Q92099877 | The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation |
Q38602011 | Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health |
Search more.